Mordenfeld Kozlovsky Nadia, Partridge Ann H, Sella Tal
Department of Oncology, Sheba Medical Center, Ramat Gan, Israel.
Department of Medical Oncology, Program for Young Adults with Breast Cancer, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02115, USA.
Ther Adv Med Oncol. 2025 Jun 18;17:17588359251346648. doi: 10.1177/17588359251346648. eCollection 2025.
Advancements in breast cancer care have significantly improved survival rates in women of all ages; however, young survivors face unique challenges related to fertility, pregnancy, and maternal-fetal health which may impact on their medical and psychosocial outcomes. Increasingly, young women are diagnosed with breast cancer before completing their reproductive plans and goals and may undergo gonadotoxic therapies and prolonged endocrine therapy with age-related fertility decline. Pretreatment counseling is critical to manage expectations, align reproductive and treatment goals, plan future childbearing opportunities, and refer for fertility preservation interventions when needed. Evidence supports the safety of pregnancy and breastfeeding in posttreatment scenarios, with individual risks and treatment histories carefully evaluated. The growing use of novel agents like CDK4/6 inhibitors, poly-ADP-ribose polymerase inhibitors, and immune checkpoint inhibitors for which there are little to no data regarding impact on fertility highlights the urgent need for further research in this area. Patient-centered, multidisciplinary approaches applied throughout the disease trajectory remain essential to support the reproductive health and overall quality of life of young breast cancer survivors navigating the reproductive complexities of modern breast cancer treatment.
乳腺癌治疗的进展显著提高了各年龄段女性的生存率;然而,年轻的幸存者面临着与生育、怀孕和母婴健康相关的独特挑战,这些挑战可能会影响她们的医疗和心理社会结局。越来越多的年轻女性在完成生育计划和目标之前被诊断出患有乳腺癌,并且可能会接受性腺毒性疗法以及随着年龄增长导致生育能力下降的长期内分泌治疗。治疗前的咨询对于管理期望、协调生殖和治疗目标、规划未来生育机会以及在需要时转介进行生育力保存干预至关重要。有证据支持在治疗后情况下怀孕和母乳喂养的安全性,需要仔细评估个体风险和治疗史。越来越多地使用细胞周期蛋白依赖性激酶4/6抑制剂、聚ADP核糖聚合酶抑制剂和免疫检查点抑制剂等新型药物,而关于这些药物对生育力影响的数据很少或几乎没有,这凸显了该领域进一步研究的迫切需求。在整个疾病进程中采用以患者为中心的多学科方法对于支持年轻乳腺癌幸存者的生殖健康和整体生活质量仍然至关重要,这些幸存者正在应对现代乳腺癌治疗中的生殖复杂性。